Latest Earnings Released (Q1 FY27): Reported quarterly statutory revenue of ₹543.51 Cr with net profit of ₹-21.27 Cr (EPS: ₹-4.16).
Exchange Disclosure (2026-10-26): Analysts/Institutional Investor Meet/Con. Call Updates —
Official listing profile for Godavari Biorefineries Limited under Diversified.
Official listing profile for Godavari Biorefineries Limited under Diversified.
Commercial & Industrial
- Strong YoY revenue expansion (330.1%)
- High earnings quality: OCF exceeds 90% of reported PAT
- Positive Free Cash Flow after capital expenditures
- Net profit decline observed YoY (-84.7%)
- Subdued Return on Equity below 6% (0.2%)
- Low Return on Capital Employed below 8% (7.2%)
| Annual Metric (₹ Cr) | FY25 Dec 2025 | FY26 Mar 2026 |
|---|---|---|
| Sales / Revenue from Operations | ₹457 | ₹1,965 |
| Operating Expenditure | ₹422 | ₹1,872 |
| Operating Profit (EBITDA) | ₹35 | ₹93 |
| Operating Profit Margin (OPM %) | 7.66% | 4.72% |
| Other Income | ₹1.81 | ₹11 |
| Finance Costs / Interest | ₹10 | ₹48 |
| Depreciation & Amortization | ₹14 | ₹54 |
| Profit Before Tax (PBT) | ₹13 | ₹1.53 |
| Tax Expense | ₹5.17 | ₹0.30 |
| Net Profit (PAT) | ₹8.10 | ₹1.24 |
| Net Profit Margin (NPM %) | 1.77% | 0.06% |
| Basic / Diluted EPS (₹) | ₹1.58 | ₹0.24 |
| Cash from Operations (CFO) | N/A | ₹173 |
| Free Cash Flow (FCF) | N/A | ₹5.05 |
| Quarterly Metric (₹ Cr) | Q2 FY25 Sep 2024 | Q3 FY25 Dec 2024 | Q1 FY26 Jun 2025 | Q2 FY26 Sep 2025 | Q3 FY26 Dec 2025 | Q4 FY26 Mar 2026 | Q1 FY27 Jun 2026 |
|---|---|---|---|---|---|---|---|
| Sales / Revenue | ₹316 | ₹445 | ₹524 | ₹426 | ₹459 | ₹568 | ₹544 |
| Operating Profit (EBITDA) | ₹-67 | ₹5.60 | ₹-23 | ₹-58 | ₹13 | ₹70 | ₹-28 |
| OPM % | -21.05% | 1.26% | -4.42% | -13.65% | 2.89% | 12.25% | -5.20% |
| Profit Before Tax (PBT) | ₹-66 | ₹8.66 | ₹-23 | ₹-58 | ₹13 | ₹70 | ₹-28 |
| Net Profit (PAT) | ₹-76 | ₹6.11 | ₹-17 | ₹-43 | ₹8.10 | ₹52 | ₹-21 |
| NPM % | -24.20% | 1.37% | -3.18% | -10.00% | 1.77% | 9.23% | -3.91% |
| Basic / Diluted EPS (₹) | ₹-18.23 | ₹1.38 | ₹-3.25 | ₹-8.33 | ₹1.58 | ₹10.24 | ₹-4.16 |
| Balance Sheet Item (₹ Cr) | FY25 | FY26 |
|---|---|---|
| Equity Share Capital | ₹51 | ₹51 |
| Reserves & Surplus | N/A | ₹722 |
| Net Worth (Shareholders' Funds) | ₹51 | ₹773 |
| Total Borrowings & Debt | N/A | ₹524 |
| Total Balance Sheet Assets | N/A | ₹2,028 |
| Cash Flow Item (₹ Cr) | FY25 | FY26 |
|---|---|---|
| Cash Flow from Operating Activities (CFO) | N/A | ₹173 |
| Cash Flow from Investing Activities (CFI) | N/A | ₹-163 |
| Cash Flow from Financing Activities (CFF) | N/A | ₹-9.50 |
| Free Cash Flow / Net Cash Flow | N/A | ₹5.05 |
| Financial Ratio / Efficiency Metric | FY25 | FY26 |
|---|---|---|
| Operating Profit Margin (OPM) | 7.66% | 4.72% |
| Net Profit Margin (NPM) | 1.77% | 0.06% |
| Return on Equity (ROE) | 15.83% | 0.16% |
| Return on Capital Employed (ROCE) | 45.49% | 3.85% |
| Return on Assets (ROA) | N/A | 0.06% |
| Debt to Equity Ratio | N/A | 0.68x |
| Interest Coverage Ratio | 3.5x | 1.9x |
| CFO to Net Profit Conversion | N/A | 139.84x |
DIN: 00295458 | Verified Board Member per SEBI LODR Reg 27 Corporate Governance Filing.
DIN: 03538688 | Verified Board Member per SEBI LODR Reg 27 Corporate Governance Filing.
DIN: 00480462 | Verified Board Member per SEBI LODR Reg 27 Corporate Governance Filing.
DIN: 09227610 | Verified Board Member per SEBI LODR Reg 27 Corporate Governance Filing.
DIN: 07831607 | Verified Board Member per SEBI LODR Reg 27 Corporate Governance Filing.
DIN: 08789423 | Verified Board Member per SEBI LODR Reg 27 Corporate Governance Filing.
DIN: 00231420 | Verified Board Member per SEBI LODR Reg 27 Corporate Governance Filing.
DIN: 09174633 | Verified Board Member per SEBI LODR Reg 27 Corporate Governance Filing.
DIN: 00200297 | Verified Board Member per SEBI LODR Reg 27 Corporate Governance Filing.
DIN: 10729351 | Verified Board Member per SEBI LODR Reg 27 Corporate Governance Filing.
| Type | Ex-Date | Record Date | Amount / Ratio | Description |
|---|---|---|---|---|
| DIVIDEND | 2026-09-15 | 2026-09-15 | ₹2.00 | Final Dividend - Rs. - 2.0000 |
| DIVIDEND | 2026-09-15 | 2026-09-15 | ₹7.00 | Final Dividend - Rs. - 7.0000 |
| DIVIDEND | 2026-09-15 | 2026-09-15 | ₹0.50 | Final Dividend - Rs. - 0.5000 |
| DIVIDEND | 2026-09-15 | 2026-09-15 | ₹5.00 | Final Dividend - Rs. - 5.0000 |
| DIVIDEND | 2026-09-15 | 2026-09-15 | ₹0.55 | Final Dividend - Rs. - 0.5500 |
| DIVIDEND | 2026-09-15 | 2026-09-15 | ₹25.00 | Final Dividend - Rs. - 25.0000 |
| DIVIDEND | 2026-09-15 | 2026-09-15 | ₹3.00 | Final Dividend - Rs. - 3.0000 |
| CORPORATE_ACTION | 2026-09-15 | 2026-09-15 | N/A | Right Issue of Equity Shares |
| DIVIDEND | 2026-09-15 | 2026-09-15 | ₹1.00 | Final Dividend - Rs. - 1.0000 |
| DIVIDEND | 2026-09-15 | 2026-09-15 | ₹0.30 | Final Dividend - Rs. - 0.3000 |
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Godavari Biorefineries Limited has informed the Exchange about Certificate under Regulation 74 (5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter 30th September, 2026
Copy of Newspaper Publication
Godavari Biorefineries Limited has informed the Exchange about Copy of Newspaper Publication relating to circular in the form of advertisment to invite deposit
Godavari Biorefineries Limited has informed the Exchange about Certificate under Regulation 74 (5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter 30th September, 2026
Godavari Biorefineries Limited has informed the Exchange about Copy of Newspaper Publication relating to circular in the form of advertisment to invite deposit
Godavari Biorefineries Limited has informed the Exchange about General Updates-- The Mexican Patent Office has granted our patent application entitled "USE OF COMPOUNDS FOR TREATING VIRAL INFECTIONS"
Quarterly distribution: Promoter 63.31% | FII N/A | DII N/A | Public 36.69%.
Godavari Biorefineries Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 28, 2026. Further, the company has informed the Exchange regarding voting results.
Every financial metric, balance-sheet balance, and shareholding breakdown displayed on this dossier is grounded in primary statutory filings submitted to Indian stock exchanges (SEBI LODR Regulations 31, 33, and 47). No data is manufactured, estimated, or interpolated.
| Data Domain | Reporting Period | Statutory Source | Ingestion Date | Status | Provenance Hash |
|---|---|---|---|---|---|
| financials_quarterly | Q1 FY27 | NSE_OFFICIAL_API | 03 Nov 2026, 19:32 | VERIFIED | 237c13030347... |
| financials_quarterly | Q1 FY27 | NSE_OFFICIAL_API | 31 Oct 2026, 20:25 | VERIFIED | 237c13030347... |
| financials_quarterly | Q1 FY27 | NSE_OFFICIAL_API | 28 Oct 2026, 15:09 | VERIFIED | 237c13030347... |
| financials_quarterly | Q1 FY27 | NSE_OFFICIAL_API | 26 Oct 2026, 02:45 | VERIFIED | cbeb65854cb4... |
| financials_quarterly | Q1 FY27 | NSE_OFFICIAL_API | 22 Oct 2026, 12:13 | VERIFIED | cbeb65854cb4... |
| financials_quarterly | Q1 FY27 | NSE_OFFICIAL_API | 17 Oct 2026, 21:45 | VERIFIED | dfc3a7a608b6... |
| financials_quarterly | Q1 FY27 | NSE_OFFICIAL_API | 13 Oct 2026, 12:47 | VERIFIED | ce0b7761c64f... |
DATA SOURCES, STATUTORY DISCLOSURES & METHODOLOGY
All corporate identifiers, listed equity data, shareholding patterns, and financial statements are extracted from official regulatory authorities: National Stock Exchange of India (NSE), BSE Limited, and Ministry of Corporate Affairs (MCA) via audited XBRL Ind-AS submissions under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Regulations 31, 33, and 47). Data is ingested and archived on official end-of-day (EOD) schedules with immutable provenance tracking.
Zero-Fabrication Policy: SRK Money Talk strictly enforces authentic data integrity. No financial values, debt levels, cash flows, or quarterly earnings are ever mathematically synthesized, interpolated, or fabricated. When statutory disclosures have not yet been filed or ingested, fields are strictly labeled as N/A or NOT_YET_AVAILABLE.
Statutory Disclaimer: The SRK Fundamental Health Score is a quantitative diagnostic algorithm based exclusively on historical audited filings and does not constitute an investment recommendation or financial advisory. Always consult a SEBI-registered investment adviser before making capital allocation decisions.